Abstract

Pompe disease is a rare metabolic disorder caused by a deficiency of the lysosomal enzyme acid α-glucosidase. Glycogen accumulation damages skeletal, cardiac, and smooth muscles, causing a progressive and debilitating muscle weakness and cardiomyopathy. As life expectancy has much improved since the introduction of enzyme replacement therapy an increasing number of patients are referred for surgical procedures. Due to the potential cardiopulmonary complications, these patients form a high-risk group for the anesthesiologist. In this study, we investigated the incidence of perioperative complications in children with Pompe disease treated in our hospital since the introduction of enzyme replacement therapy. Anesthetic and perioperative data of children with Pompe disease treated between 1999 and 2015 in the Erasmus MC-Sophia Children's Hospital, University Medical Centre, Rotterdam, The Netherlands, were collected, retrospectively. Of the 65 children with Pompe disease, 34 patients underwent in total 77, mostly low-risk, surgical procedures. Twenty-one children had the classic infantile form and 13 had a nonclassic presentation of Pompe disease. In 13 (16.8%) procedures, 1 or more perioperative complications occurred. Perioperative desaturation was the main complication (12.9%), followed by arrhythmia (3.8%) and heart failure requiring diuretic treatment (2.6%). One child died 2days postoperatively, but this was considered unrelated to the procedure. Despite the potentially high anesthetic risk for children with Pompe disease under enzyme replacement therapy, the incidence of perioperative complications in our study was relatively low. Our data suggest that with proper precautionary measures and a critical choice of timing of the operation, general anesthesia in children with Pompe disease could be relatively safe nowadays.

Highlights

  • Pompe disease is a metabolic myopathy or lysosomal storage disorder caused by an inheritable deficiency of the lysosomal enzyme acid aglucosidase

  • We provide an overview of our anesthetic experience in children with Pompe disease since the introduction of enzyme replacement therapy (ERT) in our hospital

  • We investigated the incidence of perioperative complications and risk factors making a separation between patients with classic and nonclassic presentations, and attempted to make a

Read more

Summary

Introduction

Pompe disease is a metabolic myopathy or lysosomal storage disorder caused by an inheritable deficiency of the lysosomal enzyme acid aglucosidase. Pompe disease presents as a clinical spectrum with a predicted frequency of 1:40 000. The classic infantile form of Pompe disease (1:138 000), represents the most severe end of the spectrum with generalized hypotonia, cardiomyopathy, and respiratory insufficiency as characteristic features. Without enzyme replacement therapy (ERT), these children rarely survive beyond 1 year of age due to cardiorespiratory failure. Since the diaphragm is involved pulmonary function in supine position is mostly lower than in upright position. In these patients, the heart is rarely involved.[4]

Objectives
Methods
Findings
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call